全球首创 亚辉龙中枢神经疾病检测领域实现重大突破

Core Insights - Shenzhen Yahui Long Biotechnology Co., Ltd. has received approval for its self-developed soluble CD146 detection kit (chemiluminescence method) from the Guangdong Provincial Drug Administration, marking a significant breakthrough in the detection of central nervous system diseases [1][2] - The company is the first globally to offer a soluble CD146 detection kit for cerebrospinal fluid, bringing its total number of domestic chemiluminescent reagent products to 173 [1] Group 1: Product Development and Innovation - The soluble CD146 detection kit demonstrates a notable increase in sCD146 concentration in cerebrospinal fluid among patients with multiple sclerosis (MS) and neuromyelitis optica, addressing the challenge of early and accurate diagnosis in these conditions [1][2] - Traditional laboratory testing methods have limitations, including complex procedures and long detection cycles, which the new chemiluminescence method overcomes by simplifying operations and enhancing sensitivity and specificity [1] Group 2: Clinical Implications and Market Position - The introduction of the soluble CD146 detection kit is expected to transition the field of central nervous system immune inflammatory demyelinating diseases from "diagnosable" to "precise and early diagnosis," laying a crucial foundation for disease intervention and prognosis improvement [2] - The collaboration with Academician Yan Xiyun, a prominent figure in nanobiology and tumor immunology, highlights the innovative nature of this project and strengthens China's international position in the diagnostic field for these diseases [2]